600488.SH
津药药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.17
−6.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.7B | 2.9B | 3.2B | 3.8B | 3.7B |
| Cost of Revenue | 1.6B | 1.7B | 1.8B | 2.0B | 1.9B |
| Gross Profit | 1.1B | 1.2B | 1.5B | 1.8B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 114.5M | 129.9M | 204.5M | 161.1M | 142.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 400.9M | 394.8M | 360.6M | 285.8M | 245.7M |
| Selling & Marketing Expense | 348.5M | 356.8M | 570.0M | 1.1B | 1.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 920.6M | 934.8M | 1.2B | 1.6B | 1.6B |
| Cost and Expenses | 2.5B | 2.7B | 2.9B | 3.6B | 3.5B |
| Operating Income (EBIT) | 132.2M | 189.8M | 225.6M | 169.4M | 70.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 64.1M | 122.1M | 226.5M | 168.2M | 12.5M |
| Income Tax Expense | 2.3M | 54.8K | 18.3M | 5.6M | (5.9M) |
| Bottom Line | |||||
| Net Income | 26.4M | 70.6M | 133.5M | 117.1M | 35.4M |
| Earnings from Cont. Ops | 61.8M | 122.1M | 208.2M | 162.7M | 18.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 26.4M | 70.6M | 133.5M | 117.1M | 35.4M |
| Per Share | |||||
| Basic EPS | CN¥0.02 | CN¥0.07 | CN¥0.12 | CN¥0.11 | CN¥0.03 |
| Diluted EPS | CN¥0.02 | CN¥0.07 | CN¥0.12 | CN¥0.11 | CN¥0.03 |
| Revenue Per Share | CN¥2.56 | CN¥2.68 | CN¥2.94 | CN¥3.46 | CN¥3.33 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Diluted Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | — | 485.3M | 522.2M | 442.1M | 327.2M |
| D&A | — | 295.6M | 296.7M | 272.7M | 257.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026